Abstract: Preliminary data suggest that tumor expression of programmed cell death ligand 1 (PD-L1) protein in human cancers, as determined by immunohistochemistry in formalin-fixed, paraffinembedded tissue samples, may predict clinical response to anti-PD-1/ PD-L1 therapy. PD-L1 is not a specific tumor marker and its expression is also observed in various nonmalignant cells, such as macrophages and lymphocytes, causing confusion in immunohistochemistry analysis when these inflammatory cells are overlapping with tumors cells. The aim of the current study was to examine PD-L1 expression in formalin-fixed, paraffin-embedded malignant and nonmalignant cells from human tumors to establish potential characteristic patterns of PD-L1 expression in tumor tissues. We used a commercial PD-L1 clone (E1L3N) previously validated in our laboratory to characterize PD-L1 expression in surgically resected lung adenocarcinomas, lung squamous cell carcinomas, malignant melanomas, renal cell carcinomas, hepatocellular carcinomas, and ductal breast carcinomas. We observed different patterns of PD-L1 expression by malignant cells and nonmalignant cells as membrane, cytoplasmic, and nuclear expression. The distribution of expression was variable including the entire malignant cells population, heterogonous with random distribution, peripheral distribution, minimal expression by few cells and negative expression. Similar, nonmalignant cells showed randomly and peripherally distribution through the tumors. We concluded that the PD-L1 cell protein expression patterns and distributions are variable and differ between resected tumor specimens. The expression and distribution pattern described here provide a useful knowledgment of PD-L1 expression in tumor samples.
P rogrammed cell death ligand 1 (PD-L1, also known as CD274 and B7-H1) is a major immune checkpoint protein that mediates antitumor immune suppression and response. 1 The importance of PD-L1-based immune suppression is highlighted by the advent of anti-PD-L1 immunotherapies, which have moved to the forefront of cancer treatment. 2, 3 PD-L1 is an immunomodulatory transmembrane glycoprotein with approximately 43 KDa, and it is a member of the B7 family of costimulatory molecules. 4 A wide variety of human malignancies, including melanoma, kidney cancers, and lung cancers, were recently shown to express PD-L1. The recent development of agents blocking the interaction between PD-L1 and its receptor, PD-1, has provided a new therapeutic strategy. 3 Preliminary data suggest that PD-L1 protein expression in human cancers, as determined by immunohistochemistry (IHC) in formalin-fixed, paraffin-embedded (FFPE) tissue samples, may predict clinical response to anti-PD-1/PD-L1 therapy. 1, 5, 6 However, the expression pattern of PD-L1 in FFPE sections has been shown to be heterogeneous throughout the tumor. Moreover, PD-L1 is expressed not just in tumor cells but also in a wide variety of stromal cells, including macrophages, lymphocytes, and dendritic cells, 7 with different intensities, distributions, and patterns. This makes it difficult to ensure that the interpretation of IHC 8 results is correct. Better characterization of the expression of PD-L1 in malignant cells and nonmalignant cells is needed to address this problem.
The aim of the current study was to identify different patterns of PD-L1 expression in tumor tissues and provide a useful knowledgment for the interpretation of IHC results analyzing PD-L1 expression in tumor tissue samples.
MATERIALS AND METHODS

Tumor Tissues
We used slides derived from surgically resected tissues, including lung adenocarcinoma (LADC; n = 146), lung squamous cell carcinoma (LSCC; n = 108), malignant melanoma (MM; n = 30), renal cell carcinoma (RCC; n = 30), hepatocellular carcinoma (HCC; n = 30), and ductal breast carcinoma (DBC; n = 30). These FFPE tissues had been previously transferred to slides and stained for PD-L1 for various projects in the Department of Molecular Pathology at The University of Texas MD Anderson Cancer Center.
Immunohistochemistry
All slides were stained with the E1L3N clone (clone E1L3N, Cell Signaling Technology, Beverly, MA; dilution 1:100) after it had been validated in our laboratory. 9 IHC staining of all slides was performed in an automated staining system (Leica Bond Max; Leica Microsystems, Vista, CA) using previously optimized IHC parameters and according to standard automated protocols. The PD-L1 antibody clone was detected with the Leica Bond Polymer Refine detection kit (Leica Microsystems), including diaminobenzidine reaction to detect the antibody labeling and hematoxylin counterstaining. Slides containing other human tissues (tonsil and placenta) and cell lines (PD-L1 nontransfected and transfected cell lines with the gene) were run simultaneously in each batch of staining as control slides. In addition, because macrophages and lymphocytes are known to express PD-L1, we performed multiplex immunofluorescence (mIF) staining with antibodies against CD68 (macrophages; PG-M1 clone, Dako, Carpinteria, CA; dilution 1:450), CD3 (T cell lymphocytes; Dako; dilution 1:100), PD-L1 (clone E1L3N, Cell Signaling Technology; dilution 1:3000) and AE1/AE3 pancitokeratin (epithelial cell positive, Dako, dilution 1:300) prepared according to the manufacturer's instructions 10 using the Opal 7 kit (catalogue #NEL 797001KT; PerkinElmer, Waltham, MA) and staining in an automated system (BOND-RX; Leica Microsystems) with the Opal protocol (PerkinElmer) in selected cases to determine whether PD-L1 was expressed in malignant cells, macrophages, or lymphocytes. Autofluorescence (negative control) slides were also included, using primary and secondary antibodies and omitting the fluortyramides and positive control (tonsil) were using in the run staining.
Image Collection and Analysis
The stained slides were digitally scanned using the Aperio ScanScope Turbo slide scanner (Leica Microsystems) and captured at ×200 magnification. The images were visualized using ImageScope software (Leica Microsystems), and 3 pathologists (E.R.P., P.V., and J.R.-C.) examined the whole sections of the tissues. Membranous staining of PD-L1 was considered positive PD-L1 expression, although cytoplasmic or nuclear PD-L1 staining (or any combination thereof) in individual cells was also observed. In Parallel, mIF slides were imaged using the Vectra 3.0 spectral imaging system (PerkinElmer) according to previously published instructions at ×200 magnification. 10, 11 The mIF images were visualized using InFom software (PerkinElmer). 
RESULTS
To characterize the protein expression patterns across different human FFPE tumor tissues (LADCs, LSCCs, RCCs, MMs, HCCs, and DBCs), we characterized PD-L1 expression in malignant and nonmalignant cells throughout the tissues. The protein showed clear and strong membrane or granular membrane reinforcement expression in many types of cancer cells, and this was considered positive expression, although the level of expression varied from weak to strong. Positive expression, defined as ≥ 1% of malignant cells with partial or complete membranous staining at any intensity, was found in 34 of the 146 LADCs (23.3%), 35 of the 108 LSCCs (32.4%), 7 of the 30 MMs (23%), and 2 of the 30 RCCs (6.6%; Fig. 1 ). We did not observe any positive malignant cell membranous staining in DBCs or HCCs. PD-L1 expression patterns across different cell types in each type of tumor tissue are summarized in Table 1 .
In some LADC and LSCC samples, we observed higher PD-L1 expression in the malignant cells in the invasive front of the tumor or marginal areas than in the core of the tumor (Fig. 2) , with a concomitant increase in the number of inflammatory cells in these regions. In addition, PD-L1 expression in malignant cells showed an irregular pattern, with shredded expression in different locations of the same tumor area. The heterogeneity of this marker was most notable in tumors with a solid pattern, in which we observed individual malignant cells or clusters of malignant cells staining positive for PD-L1 in samples in which most of the malignant cells were negative for PD-L1 (Fig. 3) .
Positive cytoplasmic PD-L1 expression in malignant cells was also observed with relatively high frequency, alone or mixed with positive membranous staining. We observed a variety of distribution patterns for macrophages expressing PD-L1 across the different cancer tissues we examined. The cancer tissues, and in particular in LADCs, we observed macrophages showing PD-L1 membranous staining inside of tumor glands. This was especially apparent when we analyzed PD-L1 expression in macrophages using mIF staining. CD68 staining (Fig. 4) showed PD-L1-positive macrophages in clusters in the periphery or around the tumor (AE1/AE3-positive) in association with PD-L1-positive lymphocytes, or spread in the middle of the malignant cells (Fig. 4) .
Granuloma structures also showed positive PD-L1 expression in HCCs. Specific membranous positivity was observed in multinucleated giant cells in the middle of organized granulomas (Fig. 5) , suggesting that this expression is a mirror of the constitutive expression in macrophages. Nonmalignant cells, such as type two pneumocytes in normal areas next to the tumor, sinusoidal endothelial cells from HCCs, and some normal cells from proximal renal tubules in RCCs, also showed focal PD-L1 membranous staining, although most of these cells were negative for PD-L1 (Fig. 5) .
We observed PD-L1 nuclear expression in some samples of LADC, LSCC, RCC, and HCC; this indicates nuclear immunoreactivity to the PD-L1 staining in these cells. In addition, normal cells such as hepatocytes, pneumocytes, fibroblasts, and nerve cells showed fine cytoplasmic granular staining for PD-L1, suggesting that PD-L1 could be part of the protein metabolism. PD-L1 expression was also found in nodular glomerulosclerosis regions in samples of RCC, where several fibroblasts showed cytoplasmic staining similar to that observed in normal areas (Fig. 6 ).
DISCUSSION
In this study, we examined archived tumor specimens obtained from a large cohort of patients with LADC, LSCC, RCC, MM, HCC, and DBC, for IHC expression of PD-L1 using a commercial clone (E1L3N) previously validated in our laboratory to characterize different patterns of expression by malignant cells and nonmalignant cells. We observed PD-L1 expression in membrane, cytoplasmic and nuclear expression by malignant and nonmalignant cells. The distribution of expression was variable including the entire malignant cells population, heterogonous expression with random distribution, peripheral distribution, minimal expression by few cells and negative expression. Nonmalignant cells showed randomly and peripherally distribution around the tumors. We concluded that the PD-L1 cell protein expression patterns and distributions are variable and differ between resected 
DBC indicates ductal breast carcinoma; HCC, hepatocellular carcinoma; LADC, lung adenocarcinoma; LSCC, lung squamous cell carcinoma; MM, malignant melanoma; NA, structure not observed; RCC, renal cell carcinoma; (+), positive; (−), negative.
specimens. This knowledge shown here might help to evaluate much better the expression of this protein in the tumor tissues.
The fact that PD-L1 expression is not unique to tumor cells, appearing in macrophages and lymphocytes as well, may explain the differing results among studies quantifying PD-L1 expression in tumor tissues. [12] [13] [14] [15] [16] This cell type of PD-L1 expression observed along the different tissue samples, including both malignant cells and nonmalignant cells as macrophages, represents a challenge for researchers attempting to quantify or analyze this marker using a simple staining method. Another important factor that may explain the discrepancies observed in the literature is differences in the methodology used to quantify the expression, including the antibody selected and proper validation of this antibody. Supportive evidence for the value of identify multiple markers in the same tissue section using double IHC 17 or mIF staining 18, 19 have emerged as potent tools to help a deeper understanding of the distribution of this molecules, providing an unique insight into spatial, cell type, and even phenotype colocalization-type specific distribution trying to avoid the confusions observed when is using a simple staining method. Differences in the cutoff, as previously described, 7, 13, 20, 21 at which PD-L1 expression is considered positive and heterogeneity in PD-L1 expression among specimens and between the primary tumor and its metastases are also factors to consider during PD-L1 analysis. Previously defined, positive expression as ≥ 1% of malignant cells with partial or complete membranous staining at any intensity observed by the pathologists for all tumor types analyzed in our study, provided a good cut-off point to determine if the tumor is positive or negative to the expression of this marker. Using this criteria, we observed clear membrane or granular membrane reinforcement expression, especially in solid tumors as described in the literature, 22 suggesting that this approach is very combining to identify positive tumor cases not only with this clone but with other PD-L1 commercial clones assuming that the target are only the malignant cells. Although, the minimum number of cells in general is defined by the manufacturer assay, as minimum 50 cells for the SP142 assay (Ventana) and 100 cells for 28-8 and 22C3 pharmDx assay (Agilent Technologies/Dako) we believe that 100 malignant cells are a more reliable number to avoid false positive cases in small biopsies and when the pathologist is working with different commercial clones. Interesting, no positive PD-L1 expression was observed in DBC and HCC tumor tissues, which could be because of the small number of cases.
The PD-L1 expression that we observed specifically in malignant cells located in the invasive front or in the peripheral areas of the tumor in LADC and LSCC has also been described previously in other tumors and apparently is related to an increase in the number of inflammatory cells in these regions. [23] [24] [25] The close interaction between malignant cells and inflammatory cells, especially macrophages and lymphocytes, in the invasive front or in the peripheral areas of the tumor probably activates the PD-1/DD-L1 pathway, causing PD-L1 to be expressed in tumor cells located in these regions. Some authors have suggested that this interaction between tumor cells and immune cells may also explain the heterogeneous distribution of PD-L1 expression observed in malignant cells, although the relationship between this heterogeneous distribution and the potential adaptive PD-L1 expression in tumor cells remains unclear. 26 PD-L1 cytoplasmic staining was also observed in malignant cells, but the cytoplasm is not considered the active location of PD-L1 in a cell. Cytoplasmic expression of PD-L1 in both malignant and nonmalignant cells may be related to constitutive PD-L1 expression in these cells. As reported previously, macrophages, lymphocytes, and other structures in the tumor tissues can express PD-L1. 27, 28 We believe that, similar to malignant cells, only membranous expression of PD-L1 in these cells represents active expression of the protein and suggesting that participation of the pathologist with experience in these type of markers is important to avoid false positive cases.
Multinucleated giant cells from granulomas and other nonmalignant cells, such as type 2 pneumocytes, sinusoidal endothelial cells from HCC, fibroblasts, nerve cells, and normal renal cells, can also express PD-L1, as we showed in the current study. Although, we can use these cells as an internal positives controls, the function of PD-L1 in these cells is not clear but is probably related in part to protein metabolism or external perturbations, such as ischemia caused by the surrounding microenvironment. Indeed, the pathologist need to be prepare to these situations and know that necrosis my also stain positively for PD-L1; however, cells next to these areas need to be excluded in the scoring for the determination of PD-L1 positive of malignant cells. Interestingly, some of the samples analyzed showed nuclear PD-L1 expression, which has been previously reported for us and others authors not only with this particular PD-L1 clone but also with other different clones as 22C3, 28-8, SP124 and SP 263 9 in different proportions and may indicate nuclear immunoreactivity to the PD-L1 staining. 29 In summary, we have described PD-L1 protein expression in various human tumor tissues to help in the analysis of PD-L1 expression in malignant cells. We believe that understanding the complex mechanisms behind PD-L1 expression in cells will help improve IHC analysis in FFPE tumor tissues. Further investigation is needed to elucidate the role of PD-L1 in the various cells present in the tumor microenvironment. 
